全文获取类型
收费全文 | 65695篇 |
免费 | 4740篇 |
国内免费 | 341篇 |
专业分类
耳鼻咽喉 | 666篇 |
儿科学 | 1680篇 |
妇产科学 | 1633篇 |
基础医学 | 8066篇 |
口腔科学 | 1582篇 |
临床医学 | 6540篇 |
内科学 | 14885篇 |
皮肤病学 | 914篇 |
神经病学 | 5145篇 |
特种医学 | 2025篇 |
外国民族医学 | 3篇 |
外科学 | 10171篇 |
综合类 | 1050篇 |
现状与发展 | 1篇 |
一般理论 | 105篇 |
预防医学 | 5444篇 |
眼科学 | 1890篇 |
药学 | 4622篇 |
中国医学 | 162篇 |
肿瘤学 | 4192篇 |
出版年
2023年 | 317篇 |
2022年 | 556篇 |
2021年 | 1259篇 |
2020年 | 781篇 |
2019年 | 1076篇 |
2018年 | 1353篇 |
2017年 | 909篇 |
2016年 | 1040篇 |
2015年 | 1204篇 |
2014年 | 1869篇 |
2013年 | 2926篇 |
2012年 | 3949篇 |
2011年 | 4294篇 |
2010年 | 2442篇 |
2009年 | 2272篇 |
2008年 | 4141篇 |
2007年 | 4296篇 |
2006年 | 4150篇 |
2005年 | 4209篇 |
2004年 | 3944篇 |
2003年 | 3532篇 |
2002年 | 3497篇 |
2001年 | 795篇 |
2000年 | 661篇 |
1999年 | 760篇 |
1998年 | 758篇 |
1997年 | 621篇 |
1996年 | 510篇 |
1995年 | 496篇 |
1994年 | 474篇 |
1993年 | 455篇 |
1992年 | 555篇 |
1991年 | 522篇 |
1990年 | 427篇 |
1989年 | 459篇 |
1988年 | 409篇 |
1987年 | 389篇 |
1986年 | 372篇 |
1985年 | 426篇 |
1984年 | 438篇 |
1983年 | 400篇 |
1982年 | 531篇 |
1981年 | 446篇 |
1980年 | 489篇 |
1979年 | 311篇 |
1978年 | 326篇 |
1977年 | 325篇 |
1976年 | 264篇 |
1975年 | 294篇 |
1974年 | 249篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
Pollak SJ Monir G Chernoby MS Elenberger CD 《Journal of cardiovascular electrophysiology》2005,16(3):244-248
This report describes different imaging techniques of the esophagus in four patients during radiofrequency catheter ablation of atrial fibrillation in the left atrium. A novel use of a mixture of barium cream and gadolinium diglutamate allowed esophageal imaging during magnetic resonance angiography of the left atrium and pulmonary veins. Barium cream used during computer tomography angiographic imaging of the left atrium and pulmonary veins allowed esophageal imaging. The esophagus was also imaged with an electroanatomic mapping system. Esophageal and left atrial imaging helped to avoid catheter ablation in left atrial tissue overlapping the esophagus. 相似文献
992.
Epstein-Barr Virus-Associated Membrane-Reactive Antibodies During Long Term Survival After Burkitt''s Lymphoma 下载免费PDF全文
Peter Gunvén George Klein Peter Clifford Surjit Singh 《Proceedings of the National Academy of Sciences of the United States of America》1974,71(4):1422-1426
Antibodies to Epstein-Barr virus associated cell membrane antigens persisted or slowly decreased during prolonged uncomplicated survival of patients with Burkitt's lymphoma in remission. Serum was sampled from four patients within 6 months before recurrence occurring after the first year and preceded by remission during more than 6 months. Rapid and significant decreases of the antibodies before clinical recognition of the recurrences were found in three patients. The fourth patient had slowly increasing titers before relapse. Immune stimulant treatment during remission, with BCG (Bacille Calmette Guérin vaccine) or BCG + Bordetella pertussis, temporarily increased the antibody levels. Possible mechanisms for the observed titer changes before recurrence are discussed. 相似文献
993.
Bene L Füst G Fekete B Kovács A Horváth L Prohászka Z Miklós K Pálos G Daha M Farkas H Varga L 《Digestive diseases and sciences》2003,48(6):1186-1192
Few data are available on measurements of serum concentrations of complement proteins in inflammatory bowel disease (IBD). Therefore we measured serum levels of C3, C4, and C1-esterase inhibitor (C1-INH) as well as C-reactive protein (CRP) in 167 patients with Crohn's disease (CD) and 111 patients with ulcerative colitis (UC). Median serum concentrations of C3 and C1-INH were significantly higher in CD than in UC. According to multiple logistic regression analysis adjusted to age, sex, activity of disease, and presence of extraintestinal manifestations, IBD patients with high-normal (128%, 75th percentile ) C1-INH concentrations had significantly (0.0275) higher odds ratio to have a diagnosis of CD than UC. Patients with high-normal C3 (1.40 g/liter) and high (20 mg/liter) CRP concentrations had an even higher odds ratio of a CD diagnosis (P = 0.0132). Our findings indicate that measurement of C3, C1-INH, and CRP can be used as an additional marker to pANCA/ASCA for distinguishing patients with CD and UC. 相似文献
994.
995.
996.
Robert B. Schonberger MD MHS Amit Bardia MD Feng Dai PhD George Michel MS MBA David Yanez PhD Jeptha P. Curtis MD Michelle T. Vaughn MPH Matthew M. Burg PhD Michael Mathis MD Sachin Kheterpal MD MBA Shamsuddin Akhtar MD PhD Nirav Shah MD 《Journal of the American Geriatrics Society》2021,69(8):2195-2209
997.
Brandon P. Verdoorn MD Tamara K. Evans BS Gregory J. Hanson MD Yi Zhu PhD Larissa G. P. Langhi Prata PhD Robert J. Pignolo MD PhD Elizabeth J. Atkinson MS Erin O. Wissler-Gerdes MA George A. Kuchel MD Joan B. Mannick MD Stephen B. Kritchevsky PhD Sundeep Khosla MD Stacey A. Rizza MD Jeremy D. Walston MD Nicolas Musi MD Lewis A. Lipsitz MD Douglas P. Kiel MD Raymond Yung MB ChB Nathan K. LeBrasseur PhD Ravinder J. Singh PhD Teresa McCarthy MD MS Michael A. Puskarich MD Laura J. Niedernhofer MD PhD Paul D. Robbins PhD Matthew Sorenson JD MA Tamara Tchkonia PhD James L. Kirkland MD PhD 《Journal of the American Geriatrics Society》2021,69(11):3023-3033
The burden of senescent cells (SnCs), which do not divide but are metabolically active and resistant to death by apoptosis, is increased in older adults and those with chronic diseases. These individuals are also at the greatest risk for morbidity and mortality from SARS-CoV-2 infection. SARS-CoV-2 complications include cytokine storm and multiorgan failure mediated by the same factors as often produced by SnCs through their senescence-associated secretory phenotype (SASP). The SASP can be amplified by infection-related pathogen-associated molecular profile factors. Senolytic agents, such as Fisetin, selectively eliminate SnCs and delay, prevent, or alleviate multiple disorders in aged experimental animals and animal models of human chronic diseases, including obesity, diabetes, and respiratory diseases. Senolytics are now in clinical trials for multiple conditions linked to SnCs, including frailty; obesity/diabetes; osteoporosis; and cardiovascular, kidney, and lung diseases, which are also risk factors for SARS-CoV-2 morbidity and mortality. A clinical trial is underway to test if senolytics decrease SARS-CoV-2 progression and morbidity in hospitalized older adults. We describe here a National Institutes of Health-funded, multicenter, placebo-controlled clinical trial of Fisetin for older adult skilled nursing facility (SNF) residents who have been, or become, SARS-CoV-2 rtPCR-positive, including the rationale for targeting fundamental aging mechanisms in such patients. We consider logistic challenges of conducting trials in long-term care settings in the SARS-CoV-2 era, including restricted access, consent procedures, methods for obtaining biospecimens and clinical data, staffing, investigational product administration issues, and potential solutions for these challenges. We propose developing a national network of SNFs engaged in interventional clinical trials. 相似文献
998.
999.
1000.
Helen Sawaya Kevin Johnson Matthew Schmidt Ashley Arana George Chahine Mia Atoui David Pincus Mark S. George Jaak Panksepp Ziad Nahas 《The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP)》2015,18(6)